Premium
Early Response of Specific IgE can Predict Satisfaction with Sublingual Immunotherapy
Author(s) -
Kim Jin Youp,
Rhee ChaeSeo,
Mun Sue Jean,
Cho Seong H.,
Lockey Richard F.,
Han Doo Hee
Publication year - 2021
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1002/lary.28762
Subject(s) - slit , medicine , sublingual immunotherapy , immunoglobulin e , serology , sublingual administration , cohort , immunotherapy , immunology , surgery , gastroenterology , immune system , antibody , genetics , biology
Objective To investigate predictive parameters at baseline and during the early response to sublingual immunotherapy (SLIT) for house dust mites in allergic rhinitis patients. Study Design Retrospective cohort study. Methods Patients were treated with SLIT for at least 3 years and serological tests performed at baseline and at 1‐year follow‐up to investigate predictive parameters. Satisfaction with SLIT, 4 nasal symptoms, and quality of life were evaluated before and after 3 years of SLIT. Sixty‐one patients were enrolled and divided into two groups depending on their satisfaction after 3 years of SLIT: 43 were satisfied (70.5%) and 18 were not (29.5%). Results Immunological parameters at baseline did not differ significantly between the satisfactory and unsatisfactory groups. However, changes in both Dermatophagoides pteronyssinus (Dp)– and D. farinae (Df)–specific IgEs were significantly higher in the unsatisfactory group than in the satisfactory group during the early response to SLIT ( P = .006 and P = .045, respectively). Conclusion The changes in both Dp‐ and Df‐specific IgE levels during early response may be indicators for favorable long‐term treatment outcomes with SLIT. These results suggest that clinicians could measure these immunological parameters 1 year after Dp and Df SLIT to indicate potential responders versus nonresponders. Level of Evidence 2b Laryngoscope , 131:467–472, 2021